# Zydus Targets New Growth Areas

> Zydus Lifesciences plans to expand into specialty medicines and biologics while maintaining US generics.
- Title: Zydus Targets New Growth Areas · The Economic Times | Shortify
- Summary: Zydus Lifesciences plans to expand into specialty medicines and biologics while maintaining US generics. Zydus Lifesciences will grow through specialty…
- Keywords: zydus lifesciences, specialty medicines, biologics, us generics, saroglitazar, oncology, car-t therapy, glp-1, Zydus, Targets, Growth, Areas
- Source: The Economic Times — https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-gearing-up-for-next-phase-of-growth-eyeing-new-areas-sharvil-patel-md/articleshow/134442904.cms
- Author: Rica Bhattacharyya
- Published: 2026-09-23T17:07:00+00:00
- Read time: 1 min
- Topics: zydus lifesciences, specialty medicines, biologics, us generics, saroglitazar, oncology, car-t therapy, glp-1
## Zydus Growth Strategy
Zydus Lifesciences aims to expand beyond traditional pharmaceuticals into specialty medicines and biologics.

> The focus is to build capabilities beyond traditional pharmaceuticals
## Specialty Focus
The company targets liver care, nephrology, and cardio in India with new therapeutic areas.

> In india, we want to be a very strong player in liver care
## Saroglitazar Launch
Saroglitazar aims for 18-20% US market share as Zydus enters specialty drugs.

> We are looking to target a 18-20% share of prescriptions in the us market
## Oncology Expansion
Zydus is the only Indian oncology company in the top three in the local market.

> We are the only indian oncology company in the top three in the local market
## US Generics Engine
US generics remain Zydus' largest market with room for growth.

> Us generics is still our largest market and still offers room to grow
## CAR-T Therapy
Zydus has built CAR-T therapy capabilities for next-generation treatments.

> Now we have car-t chimeric antigen receptor t-cell therapy capability
## GLP-1 Market
Oral GLP-1 drugs may dominate the diabetes market in the long term.

> In the long term, with the new molecules, i think orals will play a bigger role than injectables
## Profitability Targets
Zydus expects 24% Ebitda with improved profitability over the next five years.

> We are at around 24% ebitda and we hope to continue to improve in the next five years
## Chinese Partnerships
Zydus plans to license novel biologics from Chinese companies for unmet needs in India.

> We will also look to license for unmet needs in india for novel biologics from china
## Next Phase
Zydus will focus on specialty medicines, biologics, and US generics for sustained growth.

> We are gearing up for its next phase of growth, placing new bets on specialty medicines, complex biologics, innovative products, medical devices, and contract development and manufacturing
## Key takeaway

Zydus Lifesciences will grow through specialty medicines, biologics, and US generics while targeting 18-20% market share for saroglitazar.